Last reviewed · How we verify

Single rocuronium dose — Competitive Intelligence Brief

Single rocuronium dose (Single rocuronium dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Single rocuronium dose (Single rocuronium dose) — University Hospital, Antwerp. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Single rocuronium dose TARGET Single rocuronium dose University Hospital, Antwerp phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor
Succinylcholine Chloride SUXAMETHONIUM Novartis marketed Depolarizing Neuromuscular Blocker Muscle-type nicotinic acetylcholine receptor 1952-01-01
sufficient dose of rocuronium sufficient dose of rocuronium Korea University Guro Hospital marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor
midazolam,fentanyl,etomidate,Cisatracurium besylate midazolam,fentanyl,etomidate,Cisatracurium besylate First Affiliated Hospital Xi'an Jiaotong University marketed Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker) GABA-A receptor (midazolam, etomidate), mu opioid receptor (fentanyl), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Motivation-Phase Nicotine Mini-Lozenge Motivation-Phase Nicotine Mini-Lozenge VA Office of Research and Development marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors
NIMBEX NIMBEX Assistance Publique Hopitaux De Marseille marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor
Placebo/Galantamine (Reminyl®) Placebo/Galantamine (Reminyl®) Ludwig-Maximilians - University of Munich marketed Acetylcholinesterase inhibitor Acetylcholinesterase; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

  1. University Hospital, Antwerp · 3 drugs in this class
  2. Ain Shams University · 2 drugs in this class
  3. Merck Sharp & Dohme LLC · 2 drugs in this class
  4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
  5. Federal University of São Paulo · 1 drug in this class
  6. Korea University Guro Hospital · 1 drug in this class
  7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
  8. Ostfold Hospital Trust · 1 drug in this class
  9. St. Antonius Hospital · 1 drug in this class
  10. CHU de Reims · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Single rocuronium dose — Competitive Intelligence Brief. https://druglandscape.com/ci/single-rocuronium-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: